DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1155700
Title:
Myeloid-Derived Suppressor Cells Expressing Myeloperoxidase Directly Inhibit Adaptive Immune Cells Limiting Immunotherapy in Melanoma
Report Date:
2021-10-01
Abstract:
A recent breakthrough in treating melanoma patients is the use of immune checkpoint therapy (ICT). Unfortunately, the majority of patients do not respond to ICT. Complicating matters, is that as cancer develops, it can re-program immune cells to work in favor of tumor growth. One such population of cells are myeloid-derived suppressor cells (MDSCs). MDSCs dampen the immune system from recognizing cancer and decrease ICT treatment response. Preliminary data suggests that the enzyme myeloperoxidase is overexpressed in MDSCs. We hypothesize that by limiting the function of myeloperoxidase, we limit the effects of MDSCs to enable successful ICT response in melanoma.
Document Type:
Conference:
Journal:
Pages:
19
File Size:
2.66MB
W81XWH-18-PRCRP-CDA
(W81XWH18PRCRPCDA);
CA181152, W81XWH-19-1-0203
(CA181152, W81XWH1910203);
Contracts:
Grants:
Distribution Statement:
Approved For Public Release